ZBH enters its May 6 earnings call having just absorbed a wave of coordinated analyst target cuts — a rare pre-print repricing that sets up one of the more charged setups the orthopedic giant has seen in years.
The analyst reset is the defining feature of this setup. In a single day on April 29, seven firms — including JP Morgan, Citigroup, Wells Fargo, and Barclays — all trimmed price targets while holding their ratings unchanged. JP Morgan's Robbie Marcus cut from $100 to $95, Wells Fargo moved to $90, and Barclays maintained its Underweight with a $94 target. The message was unanimous: still investable, but less so. The mean target now clusters near $98, against a stock trading at $82.90 — a gap that sounds like upside but reflects how much the Street has already de-risked expectations. BTIG downgraded to Neutral back in late March, and Leerink initiated at Market Perform in mid-April, adding to a picture of modest but broadening caution.
The bull case rests on portfolio depth and long-term end-market recovery. Zimmer Biomet's product vitality index has improved with new launches, and the company's capital return program through buybacks provides some floor to the thesis. Bears counter that organic growth has been chronically disappointing, the Foot & Ankle division remains a drag, and the stock faces a structural valuation ceiling — the argument being that a 10x forward P/E by 2027 leaves limited room for multiple expansion. The trailing P/E on reported earnings runs elevated given normalization adjustments, while EV/EBITDA of roughly 8x on trailing numbers looks modest if growth underwhelms again.
Short interest has climbed sharply over the past month — up roughly 22% — to 5% of the free float, a meaningful build. The stock fell nearly 9% over the past week and is down about 8% over the past month to $82.90, so some of that short buildup has been rewarded. The lending market, however, is not especially tight. Borrow availability is ample and cost to borrow is modest at around 0.46%, suggesting no squeeze pressure is forming. Options tell a more constructive story: the put/call ratio has dropped to 0.68, nearly 1.6 standard deviations below its 20-day average of 0.72, indicating options traders are not positioning defensively — a meaningful contrast to what the short interest trend implies. The ORTEX short score of 46 is mid-range and declining, consistent with a position that is building but not yet extreme.
The earnings print itself will test whether the organic growth story is credible enough to halt the analyst de-rating — and whether a stock already down 8% this month has absorbed enough bad news to close the gap to those revised targets.
See the live data behind this article on ORTEX.
Open ZBH on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
